Figure 1. Viral kinetics during antiviral therapy.

(A) Eleven HCV genotype 1b partial or null-responders to interferon-based therapy were re-treated with 24 weeks of asunaprevir 100 mg (twice a day) and daclatasvir 60 mg (once daily). Seven patients responded to DAA therapy (blue) while four patients experienced virological breakthrough (orange) that occurred between weeks 4 and 12 of therapy. LLOQ, lower limit of quantitation; LLOD, lower limit of detection.

(B) HCV RNA levels (log₁₀ IU/mL) declined rapidly within the first 72 hours of therapy in both DAA responders and those with subsequent virological breakthrough. The mean reduction in log₁₀ HCV RNA IU/mL at 72 hours was 3.4 IU/mL.

(C) HCV RNA level (log₁₀ IU/mL) did not differ at baseline and at week 2 of DAA therapy between patients that responded to DAA therapy and those subsequently experienced virological breakthrough. Mean and SEM are shown.